Venetoclax (Venclexta Tablet) Post-Marketing Surveillance for CLL Patients
Status: Completed
Location: See all (13) locations...
Study Type: Observational
SUMMARY
This observational study will evaluate the safety and effectiveness of Venetoclax used in routine clinical practice for participants diagnosed with chronic lymphocytic leukemia (CLL).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:
• Participants diagnosed with chronic lymphocytic leukemia who have been prescribed Venetoclax for the first time according to the approved label
• Participants (and/or legal representative) who voluntarily agree to participate in this study and sign informed consent
Locations
Other Locations
Republic of Korea
Inje University - Busan Paik Hospital /ID# 233882
Busan
Pusan National University Hospital /ID# 216850
Busan
Kyungpook National University Hospital /ID# 233884
Daegu
Chonnam National University Hwasun Hospital /ID# 216849
Hwasun-gun
Korea University Anam Hospital /ID# 216851
Seoul
Samsung Medical Center /ID# 217180
Seoul
Seoul National University Hospital /ID# 216853
Seoul
The catholic university of korea st. Paul's hospital /ID# 238907
Seoul
The Catholic University of Korea, Seoul St. Marys Hospital /ID# 216852
Seoul
The Catholic University of Korea, Seoul St. Marys Hospital /ID# 217181
Seoul
The Catholic University of Korea, Yeouido ST. Mary's Hospital /ID# 217179
Seoul
Yonsei University Health System Severance Hospital /ID# 215348
Seoul
Ajou University Hospital /ID# 249512
Suwon
Time Frame
Start Date: 2020-04-02
Completion Date: 2025-08-18
Participants
Target number of participants: 14
Treatments
Venetoclax Participants
Participants receiving venetoclax for chronic lymphocytic leukemia according to the approved local label, and the decision to prescribe Venetoclax is independent from the enrollment into the study.
Related Therapeutic Areas
Sponsors
Leads: AbbVie